WO2011126352A3 - Médicament contre la tuberculose sur la base d'un complexe d'inclusion de cyclodextrine et de rifampicine ainsi qu'un procédé de fabrication correspondant. - Google Patents

Médicament contre la tuberculose sur la base d'un complexe d'inclusion de cyclodextrine et de rifampicine ainsi qu'un procédé de fabrication correspondant. Download PDF

Info

Publication number
WO2011126352A3
WO2011126352A3 PCT/KZ2011/000004 KZ2011000004W WO2011126352A3 WO 2011126352 A3 WO2011126352 A3 WO 2011126352A3 KZ 2011000004 W KZ2011000004 W KZ 2011000004W WO 2011126352 A3 WO2011126352 A3 WO 2011126352A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
rifampicin
cyclodextrin
tuberculosis
inclusion complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KZ2011/000004
Other languages
English (en)
Russian (ru)
Other versions
WO2011126352A2 (fr
Inventor
Кунназ Баймухановна МУРЗАГУЛОВА
Турарбек Амирханович РАКИШ
Марина Емельяновна КИМ
Калдыбай Джайловович ПРАЛИЕВ
Кайрат Мирзасалимович БЕКЕТО
Жанболат Илесович РУСТЕМБЕКОВ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joint-Stock Co "ab Bekturov's Institute Of Chemical Sciences"
ROMAT PHARMACEUTICAL Co Ltd
Original Assignee
Joint-Stock Co "ab Bekturov's Institute Of Chemical Sciences"
ROMAT PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint-Stock Co "ab Bekturov's Institute Of Chemical Sciences", ROMAT PHARMACEUTICAL Co Ltd filed Critical Joint-Stock Co "ab Bekturov's Institute Of Chemical Sciences"
Priority to EA201201098A priority Critical patent/EA201201098A1/ru
Publication of WO2011126352A2 publication Critical patent/WO2011126352A2/fr
Publication of WO2011126352A3 publication Critical patent/WO2011126352A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un médicament contre la tuberculose sur la base d'un complexe d'inclusion de cyclodextrine et de rifampicine ainsi qu'un procédé de fabrication correspondant. Cette invention se rapport à l'industrie pharmaceutique et peut s'utiliser dans des établissements médicaux pour traiter la tuberculose. Le médicament est constitué d'un complexe d'inclusion de cyclodextrine et de rifampicine avec un rapport molaire 1 :1, d'isoniazide granulé avec un polymère sensible au pH, de substances auxiliaires, à savoir un édulcorant, un désintégrateur, un hépatoprotecteur, un antioxydant et un mélange de substances lubrifiantes, à savoir un stéarate de calcium ou de magnésium et une silice sublimée, avec un rapport déclaré des composants; il permet de réduire au minimum la première étape d'absorption du médicament tout en préservant la biodisponibilité de la rifampicine à faible toxicité (dose limite (50) 5000 mg/kg) et, partant, de l'administrer aux patients, enfants ou adultes.
PCT/KZ2011/000004 2010-04-07 2011-03-29 Médicament contre la tuberculose sur la base d'un complexe d'inclusion de cyclodextrine et de rifampicine ainsi qu'un procédé de fabrication correspondant. Ceased WO2011126352A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201201098A EA201201098A1 (ru) 2010-04-07 2011-03-29 Противотуберкулезный препарат на основе комплекса включения циклодекстрина с рифампицином и способ его получения

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KZ2010/0417.1 2010-04-07
KZ20100417 2010-04-07

Publications (2)

Publication Number Publication Date
WO2011126352A2 WO2011126352A2 (fr) 2011-10-13
WO2011126352A3 true WO2011126352A3 (fr) 2011-12-01

Family

ID=44763441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KZ2011/000004 Ceased WO2011126352A2 (fr) 2010-04-07 2011-03-29 Médicament contre la tuberculose sur la base d'un complexe d'inclusion de cyclodextrine et de rifampicine ainsi qu'un procédé de fabrication correspondant.

Country Status (2)

Country Link
EA (1) EA201201098A1 (fr)
WO (1) WO2011126352A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041284A1 (fr) * 2002-10-28 2004-05-21 Council Of Scientific And Industrial Research Inclusion d'une rifampicine anti-tuberculaire avec une beta-cyclodextrine ou une 2-hydroxypropyl beta-cyclodextrine et son procede d'obtention
RU2240795C2 (ru) * 2000-08-09 2004-11-27 Панацея Биотек Лимитед Фармацевтические композиции противотуберкулезных лекарственных средств и способ их изготовления

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2240795C2 (ru) * 2000-08-09 2004-11-27 Панацея Биотек Лимитед Фармацевтические композиции противотуберкулезных лекарственных средств и способ их изготовления
WO2004041284A1 (fr) * 2002-10-28 2004-05-21 Council Of Scientific And Industrial Research Inclusion d'une rifampicine anti-tuberculaire avec une beta-cyclodextrine ou une 2-hydroxypropyl beta-cyclodextrine et son procede d'obtention

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Instruktsiya po primeneniju lekarstvennogo sredstva dlya spetsialistov RIZEF 150/150", INSTRUKTSIYA PO PRIMENENIJU LEKARSTVENNOGO SREDSTVA DLYA SPETSIALISTOV RIZEF 150/150, 5 March 2008 (2008-03-05), pages 1, Retrieved from the Internet <URL:http.//www.zakon-online.com/Admin/login.aspx?docid=2487034> [retrieved on 20110802] *
"Promyshlennaya tekhnologiya lekarstv", KHARKOV, IZDATELSTVO NFAU, MTK-KNIGA, vol. 2, 2002, pages 330 - 336 *

Also Published As

Publication number Publication date
WO2011126352A2 (fr) 2011-10-13
EA201201098A1 (ru) 2013-03-29

Similar Documents

Publication Publication Date Title
WO2009109927A3 (fr) Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
WO2006086107A3 (fr) Methodes et compositions destinees a reduire l&#39;accumulation d&#39;insuline inhalable dans les poumons
WO2007149406A3 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
MX2007010856A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer.
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
JO2932B1 (en) Lyspro insulin compounds linked to PEG
WO2010067078A3 (fr) Sels de xanthylium disubstitués en 3 et 6
WO2011008495A3 (fr) Formulations d&#39;arginase et procédés
WO2008128049A3 (fr) Procédés d&#39;administration de la tétrahydrobioptérine, compositions associées et procédés de mesure
WO2010034032A3 (fr) Procédés pour préparer des compositions de polypeptide purifié
WO2008153945A3 (fr) Compositions nutraceutiques de co-cristal
WO2007092755A3 (fr) Traitement de l&#39;insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
EP1611880A3 (fr) Compositions pharmaceutiques pour l&#39;administration sûre des médicaments dans le traitement de la narcomanie
WO2011019617A3 (fr) Vitamine d3 et ses analogues pour le traitement de l&#39;alopécie
WO2007133751A3 (fr) Formulations de polyorthoester à base stabilisée
WO2007097989A3 (fr) Composition et méthode pour administrer efficacement et sans danger un halopyruvate pour traiter un cancer
WO2011081373A3 (fr) Procédé de préparation de docétaxel cristallin anhydre hautement pur
WO2010099542A3 (fr) Formulations d&#39;atp et d&#39;analogues de l&#39;atp
WO2007130509A3 (fr) Pyrroloquinoléine quinones, et leurs procédés d&#39;utilisation
WO2008128191A3 (fr) Formes dosifiees orales de cephalotaxine
WO2008027533A3 (fr) Compositions pour soins personnels comprenant un extrait de pépins de poire
WO2020055906A8 (fr) Procédés de traitement du cancer par inhibition de l&#39;enzyme de conjugaison de l&#39;ubiquitine e2 k (ube2k)
WO2010021750A3 (fr) Procédés et compositions pour l&#39;administration de 3-halopyruvate et de composés associés pour le traitement du cancer
WO2008087774A1 (fr) Anti-oxydant
WO2007064448A3 (fr) Traitement du cancer a l&#39;aide de fts et de 2-desoxyglucose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11766203

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 201201098

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11766203

Country of ref document: EP

Kind code of ref document: A2